AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, playing catch-up with rival MSD.

When I was a boy growing up in China in the years after the Second World War, I knew a young Chinese man who had fought as a partisan against the Japanese occupying forces in Hong Kong. Not ...